Fotokoagulacja laserowa czy terapia doszklistkowa – dylematy w leczeniu cukrzycowego obrzęku plamki
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2014
Słowa kluczowe:
cukrzycowy obrzęk plamki, laseroterapia, terapia anty-VEGF
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczenie cukrzycowego obrzęku plamki stanowi dla lekarza okulisty wyzwanie terapeutyczne. Jeszcze niedawno główną metodą leczenia tego schorzenia była fotokoagulacja laserowa siatkówki, która zwykle nie prowadziła do znaczącej poprawy widzenia. Współcześnie mamy do dyspozycji skuteczne, ale kosztowne terapie doszklistkowe, w których stosuje się preparaty anty-VEGF i leki sterydowe. Dodatkowo na rynku pojawiły się lasery mikropulsowe niepowodujące uszkodzenia siatkówki. W tym kontekście niezbędne wydają się stworzenie nowego schematu leczenia cukrzycowego obrzęku plamki oraz zmiana sposobu myślenia o roli fotokoagulacji laserowej w tym procesie terapeutycznym.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Gawęcki M. Fotokoagulacja laserowa czy terapia doszklistkowa – dylematy w leczeniu cukrzycowego obrzęku plamki. Ophthatherapy [Internet]. 30 czerwiec 2014 [cytowane 22 listopad 2024];1(2):68-5. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/673
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Klein R, Klein B, Moss S et al. The Wisconsin epidemiologic study of diabetic retinopathy: the long-term incidence of macular edema. Ophthalmology. 1995; 102: 7-16.
2. Klein R, Klein B, Moss S et al. Diabetic macular edema. Ophthalmology. 1984; 91:1464-74.
3. van Leiden H, Dekker JM, Moll AC et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population. The Hoorn Study. Arch Ophthalmol. 2003; 121: 245-51.
4. Gordon B, Chang S, Kavanagh M et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991; 112: 385-91.
5. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103: 1796-806.
6. Early Treatment Diabetic Retinopathy Study research group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Arch Ophthalmol. 1987; 94: 761-74.
7. Lee C, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991; 98: 1594-602.
8. Vujosevic S, Bottega E, Casciano M et al. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010; 30(6): 908-16.
9. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review: Curr Diabetes Rev. 2012; 8(4): 274-84.
10. Beck RW, Edwards AR, Aiello L et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009; 127: 245-51.
11. Haller JA, Kuppermann BD, Blumenkranz MS et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010; 128: 289-96.
12. Campochiaro PA, Brown DM, Pearson A et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011; 118: 626-35.
13. Pearson PA, Comstock TL, Ip M et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011; 118: 1580-7.
14. Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33: 2399-405.
15. Nguyen QD, Shah SM, Khwaja AA et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117: 2146-51.
16. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118: 615-25.
17. Aiello LP, Beck RW, Bressler NM et al. Diabetic Retinopathy Clinical Research Network; Writing Committee: Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011; 118(12): 5-14.
18. Mitchell P; RESTORE extension study group. 2-Year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): an interim analysis of the RESTORE extension study. Invest Ophthalmol Vis Sci. 2012; 53: E-Abstract 4667.
19. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116: 1142-50.
20. Nepomuceno AB, Takaki E, Paes de Almeida FP et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema: Am J Ophthalmol. 2013; 156(3): 502-10.
21. Lam DS, Lai TY, Lee VY et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina. 2009; 29: 292-9.
22. Michaelides M, Fraser-Bell S, Hamilton R et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): report 1. Retina. 2010; 30: 781-6.
23. Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011; 118: 1819-26.
24. Patel JI, Hykin PG, Schadt M et al. Pars plana vitrectomy with and without peeling of inner retinal membrane for diabetic macular edema. Retina. 2006; 26: 5-13.
25. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2008; 28: 420-6.
26. Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol. 2007; 39: 69-87.
27. Polskie Towarzystwo Okulistyczne. Zasady postępowania w cukrzycowym obrzęku plamki. Online: www.pto.com.pl/dokumenty/pobierz/45,wytyczne-pto-leczenie-dme-2014.
28. Royal College of Ophthalmologist.: Diabetic Retinopathy Guidelines, December 2012. Online: http://www.icoph.org/dynamic/attachments/taskforce_documents/2012-sci-267_diabetic_retinopathy_guidelines_december_2012.pdf.
29. Mansour S, Luttrull J. Integration of MicroPulse Laser Therapy (MPLT) in the Management of Diabetic Retinopathy. [Materiały konferencyjne: IRIDEX Educational Webinar 2012].
2. Klein R, Klein B, Moss S et al. Diabetic macular edema. Ophthalmology. 1984; 91:1464-74.
3. van Leiden H, Dekker JM, Moll AC et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population. The Hoorn Study. Arch Ophthalmol. 2003; 121: 245-51.
4. Gordon B, Chang S, Kavanagh M et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991; 112: 385-91.
5. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103: 1796-806.
6. Early Treatment Diabetic Retinopathy Study research group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Arch Ophthalmol. 1987; 94: 761-74.
7. Lee C, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991; 98: 1594-602.
8. Vujosevic S, Bottega E, Casciano M et al. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010; 30(6): 908-16.
9. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review: Curr Diabetes Rev. 2012; 8(4): 274-84.
10. Beck RW, Edwards AR, Aiello L et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009; 127: 245-51.
11. Haller JA, Kuppermann BD, Blumenkranz MS et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010; 128: 289-96.
12. Campochiaro PA, Brown DM, Pearson A et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011; 118: 626-35.
13. Pearson PA, Comstock TL, Ip M et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011; 118: 1580-7.
14. Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33: 2399-405.
15. Nguyen QD, Shah SM, Khwaja AA et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117: 2146-51.
16. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118: 615-25.
17. Aiello LP, Beck RW, Bressler NM et al. Diabetic Retinopathy Clinical Research Network; Writing Committee: Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011; 118(12): 5-14.
18. Mitchell P; RESTORE extension study group. 2-Year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): an interim analysis of the RESTORE extension study. Invest Ophthalmol Vis Sci. 2012; 53: E-Abstract 4667.
19. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116: 1142-50.
20. Nepomuceno AB, Takaki E, Paes de Almeida FP et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema: Am J Ophthalmol. 2013; 156(3): 502-10.
21. Lam DS, Lai TY, Lee VY et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina. 2009; 29: 292-9.
22. Michaelides M, Fraser-Bell S, Hamilton R et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): report 1. Retina. 2010; 30: 781-6.
23. Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011; 118: 1819-26.
24. Patel JI, Hykin PG, Schadt M et al. Pars plana vitrectomy with and without peeling of inner retinal membrane for diabetic macular edema. Retina. 2006; 26: 5-13.
25. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2008; 28: 420-6.
26. Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol. 2007; 39: 69-87.
27. Polskie Towarzystwo Okulistyczne. Zasady postępowania w cukrzycowym obrzęku plamki. Online: www.pto.com.pl/dokumenty/pobierz/45,wytyczne-pto-leczenie-dme-2014.
28. Royal College of Ophthalmologist.: Diabetic Retinopathy Guidelines, December 2012. Online: http://www.icoph.org/dynamic/attachments/taskforce_documents/2012-sci-267_diabetic_retinopathy_guidelines_december_2012.pdf.
29. Mansour S, Luttrull J. Integration of MicroPulse Laser Therapy (MPLT) in the Management of Diabetic Retinopathy. [Materiały konferencyjne: IRIDEX Educational Webinar 2012].